Home/Filings/3/0001104659-19-040820
3//SEC Filing

Section 32 Fund 2, LP 3

Accession 0001104659-19-040820

CIK 0001680581other

Filed

Jul 16, 8:00 PM ET

Accepted

Jul 17, 7:41 PM ET

Size

45.0 KB

Accession

0001104659-19-040820

Insider Transaction Report

Form 3
Period: 2019-07-17
Holdings
  • Series B Preferred Stock

    Common Stock (464,285 underlying)
Holdings
  • Series B Preferred Stock

    Common Stock (464,285 underlying)
Holdings
  • Series B Preferred Stock

    Common Stock (464,285 underlying)
Footnotes (2)
  • [F1]The Series B Preferred Stock is convertible into Common Stock on a seven-for-one basis into the number of shares of Common Stock as shown in Column 3 at any time at the holder's election, and automatically upon the closing of the Issuer's initial public offering without payment of further consideration. The shares have no expiration date.
  • [F2]The reported securities are held of record by Section 32 Fund 2, LP ("Fund 2"). Section 32 GP 2, LLC (the "GP"), the general partner of Fund 2, and William J. Maris, the managing member of the GP, may be deemed to share voting and dispositive power over the shares held by Fund 2. Such person and entity disclaim beneficial ownership of shares held by Fund 2 except to the extent of any pecuniary interest therein.

Issuer

Fulcrum Therapeutics, Inc.

CIK 0001680581

Entity typeother
IncorporatedDE

Related Parties

1
  • filerCIK 0001725306

Filing Metadata

Form type
3
Filed
Jul 16, 8:00 PM ET
Accepted
Jul 17, 7:41 PM ET
Size
45.0 KB